ATE162802T1 - Amyloid-peptide - Google Patents

Amyloid-peptide

Info

Publication number
ATE162802T1
ATE162802T1 AT88303803T AT88303803T ATE162802T1 AT E162802 T1 ATE162802 T1 AT E162802T1 AT 88303803 T AT88303803 T AT 88303803T AT 88303803 T AT88303803 T AT 88303803T AT E162802 T1 ATE162802 T1 AT E162802T1
Authority
AT
Austria
Prior art keywords
amylin
kcntat
found
peptides
synthetic
Prior art date
Application number
AT88303803T
Other languages
English (en)
Inventor
Garth James Smith Cooper
Anthony Charles Willis
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE162802T1 publication Critical patent/ATE162802T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT88303803T 1987-04-27 1988-04-27 Amyloid-peptide ATE162802T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878709871A GB8709871D0 (en) 1987-04-27 1987-04-27 Peptides

Publications (1)

Publication Number Publication Date
ATE162802T1 true ATE162802T1 (de) 1998-02-15

Family

ID=10616392

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88303803T ATE162802T1 (de) 1987-04-27 1988-04-27 Amyloid-peptide

Country Status (9)

Country Link
EP (1) EP0289287B1 (de)
JP (3) JP2766647B2 (de)
AT (1) ATE162802T1 (de)
CA (1) CA1341333C (de)
DE (1) DE3856121T2 (de)
ES (1) ES2114522T3 (de)
GB (1) GB8709871D0 (de)
GR (1) GR3026640T3 (de)
HK (1) HK1003033A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454299B (sv) * 1986-10-08 1988-04-18 Westermark P Sats innehallande polypeptid som finns i pankreasoamyloid och/eller antikroppar riktade mot polypeptiden
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
EP0348490B1 (de) * 1988-01-11 1995-09-27 Amylin Pharmaceuticals, Inc. Behandlung von diabetes mellitus typ 2
US5405831A (en) * 1989-07-08 1995-04-11 Amylin Pharmaceuticals, Inc. Treatment of bone disorders
ATE128032T1 (de) * 1989-07-10 1995-10-15 Amylin Pharmaceuticals Inc Verwendung eines amylinantagonisten zur herstellung eines artzneimittels zur behandlung von fettsucht und essentieller hypertonie und damit zusammenhängenden krankheiten.
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
EP0503827A1 (de) * 1991-03-15 1992-09-16 Pfizer Inc. Verwendung von Amylin und Calcitonin-Genverwandten Peptiden und Antagonisten davon
CA2109794A1 (en) * 1991-05-24 1992-11-26 Timothy J. Rink Amylin and possibly insulin containing composition for the treatment of anorexia and related states
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
WO1993019774A1 (en) * 1992-04-03 1993-10-14 Amylin Pharmaceuticals, Inc. Amylin and possibly insulin containing composition for the treatment of anorexia and related states
JP2820797B2 (ja) * 1992-05-15 1998-11-05 アミリン・ファーマシューティカルズ,インコーポレイテッド アミリンの抗体アッセイ法
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
WO1995007098A1 (en) 1993-09-07 1995-03-16 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
EP1275635A1 (de) 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Kalzium-Rezeptor aktive Verbindungen
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
AU718254B2 (en) * 1996-01-19 2000-04-13 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
ES2326004T3 (es) 1996-05-01 2009-09-28 Nps Pharmaceuticals, Inc. Compuestos activos de receptor de ion inorganico.
DE19725619A1 (de) * 1997-06-17 1998-12-24 Fraunhofer Ges Forschung Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien
US6821954B2 (en) * 1997-09-18 2004-11-23 Auckland Uniservices Limited Compounds and uses thereof in treating bone disorders
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
EP1325028A2 (de) * 2000-09-19 2003-07-09 University Of Toronto Inhibitoren von iapp fibrillenbildung und ihre verwendungen
WO2004037168A2 (en) 2002-10-18 2004-05-06 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
DE602005021858D1 (de) 2004-02-11 2010-07-29 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
US20080004211A1 (en) * 2004-02-23 2008-01-03 Paul Fraser Inhibitors of Amyloid Fibril Formation and Uses Thereof
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US20090215069A1 (en) * 2004-07-28 2009-08-27 Andreas Christ Pancreatic polypeptide as target/marker of beta cell failure
EP2286837A3 (de) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Behandlung von Fettleibigkeit und von verwandten Krankheiten
EP1871403B1 (de) 2005-03-31 2010-09-08 Amylin Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
JP5312054B2 (ja) 2006-03-15 2013-10-09 ノボ・ノルデイスク・エー/エス アミリンとインスリンの混合物
EP2504355B1 (de) * 2009-11-25 2015-07-22 Novo Nordisk A/S Verfahren zur herstellung von polypeptiden
CN103308670B (zh) 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
CN112225808A (zh) 2012-09-12 2021-01-15 生物控股有限公司 人胰岛淀粉样多肽(hiapp)特异性抗体及其用途
US9656017B2 (en) 2014-06-20 2017-05-23 Howard E. Greene Infusion delivery devices and methods
CN110467666A (zh) * 2019-09-17 2019-11-19 湖北强耀生物科技有限公司 一种新型胰岛淀粉样多肽的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE500044C2 (sv) * 1985-02-15 1994-03-28 Gambro Lundia Ab Peptidförening, antiserum framställt med användning av denna förening samt användning av föreningen
SE454299B (sv) * 1986-10-08 1988-04-18 Westermark P Sats innehallande polypeptid som finns i pankreasoamyloid och/eller antikroppar riktade mot polypeptiden
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus

Also Published As

Publication number Publication date
DE3856121D1 (de) 1998-03-05
JPH10168099A (ja) 1998-06-23
CA1341333C (en) 2002-01-22
ES2114522T3 (es) 1998-06-01
JPS6463594A (en) 1989-03-09
JPH09133679A (ja) 1997-05-20
EP0289287A2 (de) 1988-11-02
EP0289287A3 (de) 1990-05-30
DE3856121T2 (de) 1998-07-23
JP2766647B2 (ja) 1998-06-18
EP0289287B1 (de) 1998-01-28
HK1003033A1 (en) 1998-09-30
GB8709871D0 (en) 1987-06-03
GR3026640T3 (en) 1998-07-31

Similar Documents

Publication Publication Date Title
ATE162802T1 (de) Amyloid-peptide
EP0208491A3 (en) Hybrid polypeptides and process for their preparation
EG19101A (en) Process for preparing of expression of human proapolipoprotein A.1.
HUT46638A (en) Process for producing 1,1,1-trifluoro-2,2-dichloroethane in the presence of hydrogen fluoride catalyst
IL62553A0 (en) Vectors comprising dna sequences and methods for producing recombinant dna molecules and cloning vectors
IL70414A (en) Polypeptide having human h2-relaxin activity,double-stranded dna fragments coding therefor,vectors containing the dna fragments and methods for preparing the polypeptide,dna fragments and vectors
PT73259B (en) Process for preparing novel substituted pyrazinyl-1,2,4-oxadiazole-5-ones
ZA859437B (en) Dna sequence encoding a hirudin-like protein and process for preparing such protein
DE3885366D1 (de) Verfahren zur Herstellung von Pyrrolo-(3,4-c)pyrrolen.
EP0294028A3 (en) Fluoxetine useful for the treatment of diabetes
DE69233005D1 (de) DNA kodierend für Propylendopeptidase und dessen Verwendung
HUT47136A (en) Process for producing cyclic peptides with anticoagulant effect
DE3260830D1 (en) Process for the manufacture of globin or blood cell protein and heme from hemoglobin
ZA902054B (en) Production and use of anthelmintic agents and protective immunogens
EP0712928A3 (de)
DE3888386T2 (de) Verfahren zur Herstellung von Proteinen.
PT87857A (pt) Process for the preparation of novel immunossupressant peptides
HUT53125A (en) Process for producing peptides with anticoagulant activity
EP0146903A3 (de) Herstellung eines ein Hybrid-Interferon-Spezies kodierenden Vektors
EP0281089A3 (en) Process for the preparation of factor viii:c deficient plasma, and deficient plasma obtained therwith
IL89877A0 (en) Process for the preparation of proteins which start with n-terminal proline
PT73587A (en) Process for preparing novel peptides
DE3851214T2 (de) Verfahren zur Herstellung von flachen Vorrichtungen zum Pumpen von Sauerstoff.
CS753786A1 (en) Process for the determination of /2,5-dioxo-4-imidazolidinyl/-urea in the presence of iodine complex with polyvinylpyrolidone
IT8785634A0 (it) Per cinturini in pelle per orologi.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time